Evidence map›Paper›PMID 41161755›Full record

ArticleEnvironmental health and preventive medicine2025

Japanese nationwide survey to track the impact of long COVID over 3 years.

Takuya Ozawa, Hideki Terai, Hiromu Tanaka, Arisa Iba, Mariko Hosozawa, Miyuki Hori, Yoko Muto, Eiko Yoshida-Kohno, Ho Namkoong, Shotaro Chubachi and 7 more

Abstract readMulticenter Study
In one paragraph

Article in Environmental health and preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Takuya OzawaDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine.
Hideki TeraiDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine.
Hiromu TanakaDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine.
Arisa IbaInstitute for Global Health Policy Research, Bureau of Global Health Cooperation, Japan Institute for Health Security.
Mariko HosozawaInstitute for Global Health Policy Research, Bureau of Global Health Cooperation, Japan Institute for Health Security.
Miyuki HoriInstitute for Global Health Policy Research, Bureau of Global Health Cooperation, Japan Institute for Health Security.
Yoko MutoInstitute for Global Health Policy Research, Bureau of Global Health Cooperation, Japan Institute for Health Security.
Eiko Yoshida-KohnoInstitute for Global Health Policy Research, Bureau of Global Health Cooperation, Japan Institute for Health Security.
Ho NamkoongDepartment of Infectious Diseases, Keio University School of Medicine.
Shotaro ChubachiDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine.
Ryo TakemuraDepartment of Biostatistics, Keio University School of Medicine.
Kengo NagashimaDepartment of Biostatistics, Keio University School of Medicine.
Yasunori SatoDepartment of Biostatistics, Keio University School of Medicine.
Makoto IshiiDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine.
Hiroyasu IsoInstitute for Global Health Policy Research, Bureau of Global Health Cooperation, Japan Institute for Health Security.
Koichi FukunagaDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine.
Japan long COVID research group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe long-term impact of symptom classification on quality of life (QOL) and economic outcomes among individuals with long coronavirus disease (COVID) remains poorly understood. This study aimed to clarify the situation of long COVID in Japan by analyzing patients using cluster classification.

methodsThis multicenter, retrospective cohort study enrolled 515 patients with COVID-19 and followed up for 36 months via standardized questionnaires. Patients were classified based on: 1) symptom trajectory over time and 2) symptom cluster profiles at 3 months.

resultsWhile the number of symptoms decreased, fatigue and dyspnea frequently persisted, whereas anosmia and dysgeusia declined. Cough and sputum decreased gradually. The proportion of patients with 5-9 symptoms increased. The mean (interquartile range) presenteeism scores were lower in the continuous (60 [50-80]) and relapse groups (65 [48-80]) than in the recovered group (70 [50-80]). The multiple symptoms cluster had the worst SF-36, presenteeism, and absenteeism scores (47.2 [44.7-49.8], 48.8 [27.5-72.5], and 10.9 [0.0-11.0], respectively).

conclusionsPatients with continuous and multiple symptoms experienced persistently lower QOL and greater economic burden up to 36 months after COVID-19 diagnosis. The long-term effects of long COVID are not only physical but also mental and economical. Thus, further research is needed to clarify the economical and physiological impact of long COVID.

Indexed as

COVID-19Post-Acute COVID-19 SyndromeQuality of LifeAdultAgedAged, 80 and overEast Asian PeopleFemaleHumansJapanMaleMiddle AgedRetrospective StudiesSurveys and QuestionnairesCoronavirus disease 2019COVID-19Long COVIDQuality of life

Identifiers

PMID41161755
PMCPMC12583970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.